Medtronic PLC (MDT) Stock AnalysisMDTStock AnalysisMedtronic PLC

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Medtronic PLC (MDT) is a good buy right now due to its recent strong performance metrics, including a 78% increase in global Cardiac Ablation Solutions revenue and a forward P/E ratio of 15.43, which suggests the stock is undervalued compared to its growth potential. Additionally, hedge funds have increased their buying activity by 167.88% over the last quarter, signaling strong institutional confidence. The main risk is the current market volatility and the potential impact of rising interest rates, as indicated by the Fed's recent comments, which could affect overall market sentiment.

23 analysts cover MDT: 11 rate it Buy, 12 Hold and 0 Sell. The average price target is 111.76.